FTX-6058 is under clinical development by Fulcrum Therapeutics and currently in Phase I for Sickle Cell Disease. According to GlobalData, Phase I drugs for Sickle Cell Disease have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FTX-6058’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Small molecule is under development for the treatment of sickle cell disease and beta-thalassemia. The drug candidate is administered by oral route as capsule and acts by targeting gamma-globin and selective EED-targeting PRC2. It is developed based on FulcrumSeek discovery engine.
Fulcrum Therapeutics overview
Fulcrum Therapeutics is a drug development company. The company is involved in the discovery and development of small molecule therapies to unlock gene regulation in diseases. Its pipeline products include losmapimod for treating facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058 for treating sickle cell disease and ß Thalassemia. The company also owns a proprietary product engine FulcrumSeek, which detects drug targets that can control gene expression and treat the root cause of gene misexpression. The company’s key therapeutic areas include neuromuscular, muscular, hematologic, muscle, blood and central nervous system disorders. Fulcrum Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of FTX-6058’s drug-specific PTSR and LoA scores, buy the report here.